Welcome to our dedicated page for NYSE news (Ticker: nyse), a resource for investors and traders seeking the latest updates and insights on NYSE stock.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is a clinical-stage biopharmaceutical company pioneering targeted radiotherapies for patients with advanced cancers. This news hub provides investors and healthcare professionals with timely updates on the company’s clinical developments, regulatory milestones, and strategic partnerships.
Access authoritative information about Actinium’s Antibody Radiation Conjugate (ARC) platform, including progress on lead candidates Iomab-B for bone marrow transplant conditioning and Iomab-ACT for CAR-T therapy preparation. Our curated news collection features press releases on trial results, FDA communications, and collaborations with leading cancer research centers.
Key updates include phase 3 trial data for hematologic malignancies, manufacturing advancements for radiotherapy agents, and scientific presentations at major oncology conferences. All content is vetted for accuracy and relevance to treatment innovation in cellular therapies.
Bookmark this page for streamlined tracking of Actinium’s progress in redefining cancer treatment paradigms through precision radiotherapy. Verify time-sensitive updates directly through SEC filings and official company communications.
Alexander & Baldwin (NYSE: ALEX) amended its unsecured revolving credit facility on November 6, 2025, keeping a $450 million revolver and executing a new $200 million term loan.
The company drew the full $200 million at closing, used proceeds to repay the $191 million outstanding revolver balance, and the term loan matures on November 3, 2030. Interest rate swaps lock the $200 million term loan through maturity, producing an all-in weighted average fixed rate of 4.69%. Management said the moves replenish revolving capacity, lower cost of capital, and extend the weighted average maturity of borrowings by about one year to support strategic growth.
Cars.com (NYSE: CARS) on November 6, 2025 launched Carson™, a multilingual AI search engine that converts conversational queries into targeted vehicle results to simplify filter-driven shopping.
Early performance metrics reported: Carson handles ~15% of web searches, users return 2x more, save 3x more vehicles, generate 2x more leads, and show a ~30% higher conversion from search results to vehicle detail pages. Carson surfaces Cars.com Award winners and understands practical, emotional, lifestyle and specific automotive queries. Planned enhancements include AI summaries, refinement prompts, filter suggestions and personalized comparisons.
Adient (NYSE: ADNT) reported fourth-quarter and full-year fiscal 2025 results on Nov. 5, 2025. Q4 GAAP net income was $18M with diluted EPS of $0.22 and adjusted diluted EPS of $0.52. Q4 adjusted EBITDA was $226M with an adjusted EBITDA margin of 6.1%. For FY25 the company generated $204M of free cash flow and repurchased $125M of shares, equal to ~7% of outstanding shares at the start of the year.
Balance sheet figures at Sept. 30, 2025 included gross debt ~$2.4B, net debt ~$1.4B, and cash $958M. For FY26 management expects improved business performance but warns that lower customer production volumes and increased growth investments will offset gains. An investor conference call occurred Nov. 5, 2025 at 8:30 a.m. ET.
Actinium Pharmaceuticals (NYSE American: ATNM) announced that Sandesh Seth, Chairman and CEO will participate in the Stephens Biotechnology Virtual Fireside Chat on November 4, 2025 from 10:30–11:20 am ET. Company management will be available for one-on-one investor meetings during the virtual event. Investors or advisors seeking to join meetings or request more information should contact their Stephens representative.
Cars Commerce (NYSE: CARS) released its Q3 2025 Industry Insights Report showing a steady U.S. auto market as pricing, production sourcing and incentives influenced activity.
Key points: average new-car price near $49,000 (+0.5% YoY); 2026 models represented one-third of dealer inventory by end of September; U.S.-built vehicles were 56% of dealer inventory in early October; EV wholesale values fell 10.4% QoQ and 17% YoY. The report cites incentives, tariff effects and earlier model-year rollouts as drivers.
Aon (NYSE: AON) reported third-quarter 2025 results for the three months ended September 30, 2025, with $3.997B total revenue, up 7% year-over-year and 7% organic revenue growth. Operating income rose to $816M (+31%) and operating margin improved to 20.4% (up 370 bps). Diluted EPS was $2.11 (+34%) and adjusted EPS was $3.05 (+12%). Cash provided by operations was $1.148B (+13%) and free cash flow was $1.079B (+13%) for the quarter. Risk Capital revenue was $2.5B (+7%) and Human Capital revenue was $1.5B (+8%). The company repurchased ~0.7M shares for ~$250M and has ~$1.6B remaining repurchase authorization.
Management reiterated confidence in achieving full-year 2025 guidance and emphasized execution of its Aon United 3x3 Plan and continued investments via Aon Business Services.
Philip Morris International (NYSE:PM) announced on October 28, 2025 that its U.S. businesses (PMI U.S.) were certified as a Great Place to Work and recognized as a USA TODAY Top Workplace, including honors for Top Woman-Led Company and excellence in professional development, employee appreciation, and well-being.
The recognition is based on direct employee feedback and workplace evaluations and builds on other national honors, including being named one of America's Best Companies 2025 by Forbes and being highlighted by U.S. News & World Report for project management leadership tied to the 2025 Pulse of the Profession report. PMI U.S. employs more than 3,000 people in the U.S. and operates manufacturing sites in Owensboro, Kentucky, and Wilson, North Carolina.
Actinium Pharmaceuticals (NYSE: ATNM) presented preclinical data on ATNM-400, a first-in-class Ac-225 antibody radioconjugate targeting a non-PSMA antigen, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat on Oct 24, 2025. ATNM-400 showed superior tumor control and prolonged survival versus enzalutamide, 177Lu-PSMA-617 and 225Ac-PSMA-617 in 22Rv1 and other models, including ~5× longer tumor control and ~2× longer overall survival versus 177Lu-PSMA-617. Combination with enzalutamide produced complete regressions in 40% of animals. Data support PSMA-independent activity and potential use as monotherapy, combination, or sequential therapy.
Actinium Pharmaceuticals (NYSE: ATNM) announced that first-ever preclinical data for ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, will be presented at the AACR-NCI-EORTC conference Oct 22–26, 2025.
Preclinical findings reportedly show potent anti-tumor activity in EGFR-mutant NSCLC models, overcoming resistance to osimertinib and showing synergy with osimertinib and with enzalutamide in prostate models; animal data included 40% complete tumor regressions in a prostate setting. The poster is scheduled for Oct 25, 2025, and the abstract will be available online Oct 22, 2025 at 12:00 PM ET.
Actinium (NYSE: ATNM) announced that preclinical data for ATNM-400, a first-in-class Ac-225 antibody radioconjugate, will be presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat on October 23, 2025. The poster highlights durable anti-tumor activity in metastatic castration-resistant prostate cancer models, including activity in tumors resistant to enzalutamide and 177Lu-PSMA-617, and reports superior efficacy versus 225Ac-PSMA-617.
The release states ATNM-400 targets a distinct, non-PSMA antigen that is overexpressed after ARPI therapy, showed synergy with enzalutamide, and improved overall survival in preclinical models. The poster will be viewable online via the company investor relations page after the retreat.
